Castle Biosciences (CSTL) Change in Receivables (2018 - 2026)

Castle Biosciences has reported Change in Receivables for 9 years, with the latest figure at $5.8 million in Q2 2026.

• Quarterly Change in Receivables rose 248.77% year-over-year to $5.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.4 million (down 154.36% YoY) and the FY2025 annual result came in at -$6.9 million, down 154.39% from the prior year.
• Change in Receivables advanced to $5.8 million in Q2 2026 per CSTL's latest filing, from -$1.1 million in the prior quarter.
• Over five years, Change in Receivables peaked at $5.8 million in Q2 2026 and troughed at -$6.3 million in Q4 2025.
• A 5-year average of $1.8 million and a median of $2.8 million in 2022 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables surged 11502.0% in 2023, then tumbled 915.6% in 2025.
• Over 5 years, Change in Receivables stood at $540000.0 in 2022, then jumped by 113.15% to $1.2 million in 2023, then sank by 33.19% to $769000.0 in 2024, then sank by 915.6% to -$6.3 million in 2025, then jumped by 192.75% to $5.8 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $5.8 million, -$1.1 million, and -$6.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.